Smith+Nephew's TESSA Spatial Surgery System Wins FDA De Novo Classification in Sports Medicine

The Quick Take

• Smith+Nephew (SNN) received FDA De Novo classification for its TESSA Spatial Surgery System, a significant regulatory milestone.
• TESSA enables personalized preoperative planning and procedural innovation in sports medicine, marking a generational leap in surgical technology.
• De Novo classification opens the US market for a category of spatial surgery device that lacked a predicate, giving Smith+Nephew a first-mover regulatory advantage.

Smith+Nephew, the global medical technology company listed on both the London Stock Exchange (SN.L) and NYSE (SNN), received FDA De Novo classification for its TESSA Spatial Surgery System — a spatial computing platform designed to enable personalised preoperative planning and real-time procedural guidance in sports medicine procedures. The De Novo pathway is reserved for novel low-to-moderate risk devices that lack a predicate device, meaning TESSA is the first of its kind to receive this regulatory designation. This creates a significant first-mover advantage: subsequent entrants in this category will be required to demonstrate substantial equivalence to TESSA rather than to an independent standard.

The FDA clearance is a materially positive catalyst for Smith+Nephew's orthobiologics and sports medicine segment, which competes directly with Stryker, Zimmer Biomet, and Arthrex in the US surgical market. Spatial surgery — where mixed-reality or spatial-computing overlays guide surgical instrument positioning in real time — represents a high-growth adjacency to the established $5B-plus US sports medicine market. Approval at the De Novo level rather than through the 510(k) pathway signals that TESSA's clinical evidence package was sufficiently robust to establish a new device category, a distinction that often supports premium procedure pricing and stronger hospital adoption rates.

The key forward signal is Smith+Nephew's commercialisation timeline and early US hospital adoption data for TESSA, expected in the next two to four earnings quarters. Watch surgeon and hospital system feedback at the American Academy of Orthopaedic Surgeons (AAOS) upcoming meetings for early adoption indicators. The macro variable is US hospital capital spending: if hospital systems tighten capex budgets due to reimbursement pressure or higher borrowing costs, the pace of spatial surgery platform adoption could slow even with strong clinical evidence. Smith+Nephew's ability to articulate a clear cost-per-procedure economics case will be decisive for broad TESSA market penetration.

Synthesized from 1 source.